Acumen Pharmaceuticals Reveals Groundbreaking Presentations for 2025 Events
Acumen Pharmaceuticals' Promising Presentations for 2025 Events
NEWTON, Mass. – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), renowned for its cutting-edge research and development in Alzheimer’s treatments, is set to showcase groundbreaking presentations at major international conferences in 2025. The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders will take place in Vienna, Austria, alongside the American Academy of Neurology Annual Meeting in San Diego, California.
Key Presentations at the International Conferences
Acumen's presentations will emphasize the advances being made with sabirnetug (ACU193), a novel therapeutic targeting soluble amyloid beta oligomers (A?Os), which are pivotal in Alzheimer’s progression. These gatherings provide an opportunity for Acumen to share critical findings from ongoing clinical trials while fostering engagement with global thought leaders in neurology.
Oral Presentations Highlighting Innovative Research
The oral presentation titled ALTITUDE-AD: Use of Plasma pTau217 Screening in An Ongoing Phase 2 Study of Sabirnetug for Early Symptomatic Alzheimer's Disease will be delivered on April 1, 2025. This vital presentation is scheduled for 2:30-2:45 p.m. at the Austria Center Vienna, Hall A, presented by Eric Siemers.
Poster Presentations to Discuss Technical Advances
Additionally, poster presentations on April 2-3, 2025, will delve into various aspects of Acumen’s research:
- Protocol for the Preparation of Stable Monomeric Amyloid Beta by Erika Cline at the Exhibition Hall.
- Utility of Human iPSC-Derived Neuronal Model for Evaluating Synaptic Binding of Amyloid Beta Oligomers presented by Elizabeth Johnson in the same location.
American Academy of Neurology Annual Meeting Details
At the American Academy of Neurology Annual Meeting, Acumen will present the ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer's Disease on April 7, 2025. This session, delivered by Todd Feaster, will explore the implications of utilizing the plasma pTau217 assay to inform participant selection.
Highlights of the Poster Session at AAN
Also scheduled is a poster presentation on April 9, 2025, regarding INTERCEPT-AD Biomarker Results: Early Effect of Sabirnetug Treatment on Synaptic Biomarkers in Alzheimer's Disease. Elizabeth Johnson will discuss findings from this significant study during the poster session at the San Diego Convention Center.
Understanding Sabirnetug (ACU193)
Sabirnetug (ACU193) signifies a remarkable development in Alzheimer’s treatment, providing a targeted approach against toxic soluble A?Os that inhibit neurofunction and provoke neurodegeneration. With Fast Track designation from the U.S. FDA, this promising therapeutic aims to address an urgent need in treating early symptomatic Alzheimer’s disease.
Diving into ALTITUDE-AD Trial
The ongoing ALTITUDE-AD study is a pivotal Phase 2 clinical trial initiated to validate the effectiveness and safety of sabirnetug (ACU193) administered to early Alzheimer's patients. Designed as a multi-center, randomized, double-blind trial, it aims to evaluate the potential of this treatment to slow cognitive and functional decline in approximately 540 participants.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a leading clinical-stage biopharmaceutical company relentless in its pursuit to innovate therapeutic solutions targeting Alzheimer’s disease. Through advanced research into A?Os, Acumen aims to revolutionize the treatment landscape for this debilitating condition. Following promising outcomes in earlier trials, the company is committed to delivering effective interventions to patients facing Alzheimer’s. For more information, visit www.acumenpharm.com.
Frequently Asked Questions
What is Sabirnetug (ACU193)?
Sabirnetug (ACU193) is a humanized monoclonal antibody designed to target toxic A?Os, which are implicated in the development of Alzheimer's disease.
When and where will Acumen present its research?
Acumen will present at the International Conference on Alzheimer’s and Parkinson’s Diseases from April 1-5, 2025, and at the American Academy of Neurology Annual Meeting from April 5-9, 2025.
Who are the presenting authors for the oral presentations?
Eric Siemers will present at the AD/PD conference, while Todd Feaster will represent Acumen at the AAN conference.
What is the ALTITUDE-AD trial?
ALTITUDE-AD is a Phase 2 clinical trial assessing the safety and efficacy of sabirnetug in slowing cognitive decline in early Alzheimer’s disease patients.
How can I learn more about Acumen Pharmaceuticals?
Further information is available through Acumen’s official website, showcasing their ongoing research and commitment to Alzheimer's treatments.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
